Durham eye disease firm’s new CEO comes on board with $5M ‘inducement grant’
Aerie Pharmaceuticals is paying a hefty price to secure the services of its new chief executive officer. Here are the details.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
